PROBLEM

Every year, thousands of preventable deaths occur due to missed or delayed recognition of internal blood loss, fluid imbalance, or circulatory collapse—conditions that can rapidly spiral in trauma, dialysis, or childbirth.

Existing tools are either invasive, intermittent, or inadequate:

  • In trauma care, internal hemorrhage is often invisible until it's too late

  • In dialysis, patients are frequently over- or under-treated, with no real-time insight into their actual vascular volume.

  • In maternal health, postpartum hemorrhage remains a leading cause of preventable mortality—especially in low-resource settings.

 
 

SOLUTION

Avalyra is reimagining the future of non-invasive monitoring. Our current R&D Pipeline is designed to deliver:

  • Real-time data on fluid and blood volume shifts

  • Non-invasive, wearable form factor

  • Cloud-based insights for clinicians and field responders

  • AI-ready architecture for predictive care pathways

By detecting subtle physiological changes before they escalate, Avalyra Biophotonics devices are designed to enable earlier intervention, support safer outcomes, and optimize use of clinical resources.

 

TRACTION

 
 

  • Human Data Validation: Core technology has already been tested in small-scale feasibility studies on human subjects, including use cases for dialysis and internal bleeding.

  • SBIR-backed Development of the Core IP: Technology development has been previously funded through Phase I and II SBIR grants.

  • Demo Units Built: Multiple demo devices are available and undergoing clinical revalidation.

  • Government & Clinical Partners Engaged: Avalyra Biophotonics is currently preparing for a federal CRADA and strategic licensing engagements in support of a Phase III SBIR. 

  • Seed Raise Underway: We’re raising early-stage seed capital to accelerate commercialization and initiate clinical trials with a national dialysis provider.

 

Avalyra Biophotonics is SAM.gov registered and qualified to serve as a government prime contractor.

 

Past Performance / De-Risking Milestones to Date

 
 

  • Foundational Embodied IP funded via U.S. Army SBIR Phases I & II

  • Functional demos tested in IRB-reviewed human observational use

  • IRB-approved dialysis trials planned for Q3/Q4 2025

  • FDA, CMS, CRADA, and Strategic Licensing engagement roadmaps in place